Data for each of the four tumor stages were assessed independently; 37.5% (3/8) of stage T1 samples, 20% (5/25) of stage T2 samples, 31.7% (13/41) of stage T3 samples, and 50% (5/10) of stage T4 samples were positive for FOXC2 expression. This evidence concerns the gene FOXC2 and neoplasm.